pSivida: a leading company in ophthalmic drug delivery

Presenting on the above topic is Brian Leedman,Vice President,pSivida, Australia. He will be speaking at 5th Annual BioPharma Asia Convention 2012, held on 19th to 22nd March 2012 at Marina Bay Sands, Singapore. He will be conducting an on-floor seminar at Theatre 3 at 11:30 on the 21st of March.

About pSividia:
pSivida is a global leader in the sustained release of drugs to the back of the eye for the treatment of chronic ophthalmic diseases. pSivida has developed two FDA approved products and has completed Phase III clinical trials of the lead product candidate, Iluvien for the treatment of Diabetic Macular Edema – awaiting European approval. pSivida has a licensing agreement with Pfizer (10% shareholder) and is in clinical trials for the sustained long-term release of Latanoprost for the treatment of Glaucoma. pSivida is also in clinical trials for the treatment of Uvietis and is developing a next generation fully bioerodible delivery system for the release of small drug molecules such as proteins and antibodies. pSivida is listed on the Nasdaq, FF and ASX.

To find out more about them,Click here to view the full list of on-floor seminars and register your interest now!

If you are keen to find out more, join us at BioPharma Asia Convention 2012 to gain valuable insights from more than 200 experts. Contact us now for more details!

Leave a Reply

Your email address will not be published. Required fields are marked *